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Leiomyosarcoma of bone is just one of the variants of spindle cell sarcoma of bone characterised by the expression of desmin and
other markers indicating a signiﬁcant element of smooth muscle in the tumour, without osteoid production we have investigated
themanagement andoutcomeofthisraretypeofprimarymalignant bonetumour.Method.Retrospective review ofdatastoredon
a prospective database. Results. In a database of 3364 patients with primary malignant bone sarcomas, 31 patients were identiﬁed
with a primary leiomyosarcoma of bone. There were 12 males and 19 females with a mean age of 46 and tumour size of 8cm. The
most common site was the distal femur followed by the proximal tibia. Treatment was with chemotherapy and surgical resection.
Seven of the patients had metastases at diagnosis. Surgery was carried out in 28 patients, 8 having amputation and 20 limb salvage.
Three patients developed local recurrence, but half developed metastases. All patient disease-speciﬁc survival was 57% at ﬁve years
and 44% at 10yrs but for those without metastases was 82% and 60%, respectively. The only prognostic factors were metastases
at diagnosis. Conclusion. Leiomyosarcoma of bone is a very rare primary malignant bone tumour aﬀecting a predominantly older
population. Despite the high incidence of metastases, survival is better than for other bone sarcomas for those without metastases
at diagnosis.
1.Introduction
Primary malignant bone tumours are rare with an incidence
of approximately 9 million population per year. The most
commononesareosteosarcoma,Ewing’ssarcoma,andchon-
drosarcoma, but a variety of other smaller groups exist, some
with speciﬁc features (e.g., chordoma) but others have a
variety of diﬀerent histotypes. Over the years these have been
categorised variously as ﬁbrosarcoma, MFH, and spindle cell
sarcoma, but recent immunohistochemical methods have
sometimes allowed more speciﬁc characterisation.
Leiomyosarcomas (LMSs) are usually malignant soft
tissue tumours with smooth muscle diﬀerentiation apparent
with immunohistochemical or electron microscope studies
(WHO). They can also occur as primary in bone, or
secondary metastasising from a distant source (e.g., a pri-
mary leiomyosarcoma either of soft tissue or sometimes the
uterus). They were ﬁrst described in 1965 by Evans and
Sanerkin [1] in the proximal tibia of a 73-year-old man and
havesincebeenslowlyacceptedinpublisheddataasaunique
classiﬁcation described in the literature by series of small
case studies. To our knowledge, around 90 cases have been
described with the largest by Antonescu et al. in 1997 [2].
We have reviewed our experience of treating patients
with primary leiomyosarcoma of bone between 1989 and
2011, trying to identify prognostic indicators and outcomes.
2. Patients andMethods
All patients diagnosed with a primary leiomyosarcoma of
bone, treated at the Royal Orthopaedic Hospital, Birming-
ham were included in the study from 1970 to 2011. 35
patients were identiﬁed from the database of 3364 with a pri-
mary bone sarcoma (<1%). Four patients were excluded as
they were only referred for advice or had no treatment at
our centre. All patients underwent complete staging with
bone scans and CT chest with MRI of the aﬀected bone
after 1992. In female patients, the possibility of this being
a metastasis from a uterine leiomyosarcoma was excluded
by history and appropriate scans. Throughout this time
period, patients were treated in the same manner as patients2 Sarcoma
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Figure 1: (a) Microscopic appearance of leiomyosarcoma-pleo-
morphic spindle cells with atypical cells, (b) typical macroscopic
ﬂeshywhiteappearancewith3fociofnecrosisofaleiomyosarcoma.
with osteosarcoma, receiving chemotherapy if they had a
high grade tumour and were under the age of about 60.
Patients with low-grade tumours or much over the age of 60
had no chemotherapy but had surgical resection aiming to
achieve clear margins. Throughout this time period, the
most common chemotherapy drugs used were cisplatin and
adriamycin.
Data was collected from the prospectively compiled
database, and further information was obtained from the
medical records. Patient, tumour, treatment, and outcome
data was recorded. This included year of diagnosis, grade,
Enneking stage, site, biopsy type, presence of fracture at
presentation, size, surgical procedure, surgical and patho-
logical margins, chemotherapy, presence of metastasis at
diagnosis and during follow up, and date/cause of death if
applicable. Treatment details included the initial treatment
(surgery versus chemo), the type of surgical intervention, the
surgical and pathological margins, and the timing/regime of
chemotherapy. Follow-up data included the time to local
recurrence, time to metastasis, time to last followup if alive,
or time to death.
Statistical analysis was carried out using Statview.
Kaplan-Meier survival curves were used to show survival,
and univariate analysis with Cox regression was used to try
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Figure 2: Histogram to show the distribution of age at diagnosis.
and identify potential prognostic factors. Signiﬁcance was
taken with a P value < 0.05.
3.DiagnosticFeatures
Primary leiomyosarcoma of bone shows smooth muscle
diﬀerentiation with immunohistochemical studies. Macro-
scopically, these lesions appear as ﬂeshy, greyish white
tumours with areas of necrosis (Figure 1). Histologically, the
features are similar to leiomyosarcoma of any other site and
are characterised by fascicles of plump pleomorphic spindle
cells which show marked cytological atypia (Figure 1). The
tumour lacks osteoid. Immunohistochemically, the cells
show positive staining with smooth muscle actin, desmin,
and caldesmon. The diagnosis of leiomyosarcoma of bone
wasmadeinallcasesonthebasisoftheabovecriteriaapplied
retrospectively for cases diagnosed earlier in the series
when desmin was not available. If the resection specimen
contained osteoid, then the tumour was reclassiﬁed as an
osteosarcoma. Cases where a soft-tissue leiomyosarcoma
invaded bone secondarily were excluded.
4. Results
Of the 31 eligible patients identiﬁed from the oncology
database, 12 were male and 19 female (39%:61%
male:female). The median age at diagnosis was 46 years old,
r a n g i n gf r o m9t o8 8y e a r s( Figure 2).
T h em o s tc o m m o ns i t ea ﬀected was the distal femur in
14 patients (45%), followed by proximal tibia in 8 patients
(26%), and proximal humerus in 2 patients (6%). Other
sites aﬀected included the mid-shaft of the clavicle, distal
humerus, proximal ﬁbula, ileum, blade of scapula, and
distal tibia, each in 1 patient (3%). 13 of 31 (42%) had a
pathological fracture, four of whom had it ﬁxed before the
diagnosis was made.
The median size of the tumour at diagnosis was 8cm.
Five were low-grade tumours (16%) and 26 were of high
grade. Five patients were staged as Enneking stage 1b, four
were stage 2a, and 15 were 2b. Six patients had metastasesSarcoma 3
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Figure 3: Kaplan-Meier plot indicating survival by the stage of
leiomyosarcoma.
at the time of diagnosis (stage 3); four patients (13%) had
deposits in the lungs, while one patient had metastases in the
lymph nodes, and one in a distant bone.
18 of the 31 patients (58%) had chemotherapy, with 17
of those 18 having neoadjuvant chemotherapy. Only 3 of
17 patients had >90% necrosis in the resected specimen.
30 of the 31 patients (97%) had surgical resection with
eighthavingamputations,twoboneresectionsand20having
endoprosthetic replacements. Surgical margins were wide in
24 (80%), marginal in ﬁve and intralesional in one.
Local recurrence occurred in three patients. This was
not statistically related either to the margins of excision, or
the presence of a pathological fracture, or the response to
chemotherapy. Two of the three subsequently developed
metastases and died.
The overall survival rate was 62% at ﬁve years (Figure 3).
The survival rate and prognosis were closely related to stage
ofdiagnosis; allpatients withstage1or2asurviving,patients
with stage 2b tumours had a 60% survival at 5 years, 43%
survivalat10and15years,andpatientswithstage3tumours
had a median survival of 2 years, but all had died within four
years.
The response to chemotherapy was analysed in the 15
patients with stage 2b tumours who had chemotherapy.
Although not statistically signiﬁcant, those whose response
to chemotherapy showed a greater than 90% necrosis
appeared to have a better prognosis (Figure 4).
Statistically the only factor associated with improved
survival was the absence of metastases at diagnosis (P =
0.0053).
5. Discussion
Preexisting data on primary leiomyosarcoma is limited sim-
ply due to the low incidence of this rare tumour. Historically,
since the discovery and diagnosis of this type of tumour as
a separate entity in 1965 [1], most cases have been presented
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Figure 4: Kaplan-Meier plot indicating result of chemotherapy
necrosis on survival (P = 0.3).
as small case series [3–10] leading to diﬃculty in extrapolat-
ing results to the whole patient population.
Adelani et al., (2009) [3] found the median age aﬀected
to be 47 years, with a range from 9 to 87 years, while the
median age in our series was 46, ranging from 9 to 88 years.
Generally, it is felt that there is an equal distribution between
the sexes for primary leiomyosarcomas [2, 7, 8]; however,
our series reﬂects a slight male predominance, as do several
other smaller studies [9, 11, 12]. In terms of tumour locality,
our cohort agreed with the consensus that long bones
are primarily aﬀected, predominantly the distal femur and
proximal tibia with 45% and 26% of patients, respectively
[2, 5, 13, 14]. Interestingly, other studies have found the
craniofacial skeleton to be the second most common area
aﬀected, while none of our patients had skull tumours, this
most likely reﬂecting our local referral practice [15–19].
Surgical excision with wide margins remains the gold
standardforcurativemanagement,amputationusuallybeing
reserved for tumours surrounding the neurovascular bundle,
or with extensive soft tissue involvement. In our series, the
majority of those surgically treated had limb salvage (73%),
the relatively high amputation rate (8 of 30, 27%) being
largely due to pathological fractures in four and extensive
softtissueinvolvementintheothers.Theroleofpreoperative
chemotherapy remains debatable, [2, 3]r e ﬂ e c t e db yo u r
cohort; 58% received chemotherapy, and only 18% achieved
>90% necrosis (this being considerably less than the 36% for
patients treated for osteosarcoma over the same time period)
[20]. Although not statistically signiﬁcant, those patients
who did respond well to chemotherapy had a trend towards
better survival.
Many of the case series published have reﬂected a poor
prognosis, although no one has successfully stratiﬁed the
risk according to stage/grade. Antonescu et al. produced the
largest series to our knowledge [2], presenting 33 patients
with primary leiomyosarcoma between 1977 and 1996. They
had an average follow-up period of 30 months and found
no signiﬁcant diﬀerences in disease free of overall survival4 Sarcoma
rates between low- and high-grade tumours. In that series,
only 21% had neoadjuvant chemotherapy, and there was
no clear diﬀerence in survival between those treated with
chemotherapy and those without. More recently, Rekhi et al.
[10] presented a series of 8 cases, none of whom had
chemotherapy.Allthepatientswentontodevelopmetastases
within 12 months following the original diagnosis leading
the authors to conclude that it was a dismal condition to
have.
This study has shown that prognosis is based on the stage
of diagnosis; with Enneking stages 1b or 2a cases achieving
100% survival, stage 2b tumours having a 60% survival at 5
years and 43% survival at 10 and 15 years. These ﬁgures are
certainly comparable with survival of patients treated with
osteosarcomaoverthesametimeperiodwhichaveraged56%
for patients with high-grade nonmetastatic disease [21].
In conclusion, primary leiomyosarcomas of bone are
aggressive tumours which should be treated just like osteo-
sarcoma but which, in our experience, have a slightly better
prognosis than patients with osteosarcoma. The optimum
chemotherapy regime, like for osteosarcoma, remains to be
established, but surgically they should be excised with clear
margins, like other bone sarcomas.
References
[ 1 ] D .M .E v a n sa n dN .G .S a n e r k i n ,“ P r i m a ryl e i o m y o s a r c o m ao f
bone,” The Journal of Pathology and Bacteriology, vol. 90, no. 1,
pp. 348–350, 1965.
[ 2 ] C .R .A n t o n e s c u ,R .A .E r l a n d s o n ,a n dA .G .H u v o s ,“ P r i m a r y
leiomyosarcoma of bone: a clinicopathologic, immunohis-
tochemical, and ultrastructural study of 33 patients and a
literature review,” American Journal of Surgical Pathology, vol.
21, no. 11, pp. 1281–1294, 1997.
[ 3 ]M .A .A d e l a n i ,S .J .S c h u l t e n o v e r ,G .E .H o l t ,a n dJ .M .
M. Cates, “Primary leiomyosarcoma of extragnathic bone:
clinicopathologic features and reevaluation of prognosis,”
Archives of Pathology and Laboratory Medicine, vol. 133, no. 9,
pp. 1448–1456, 2009.
[4] H. Atalar, C. Gunay, Y. Yildiz, and Y. Saglik, “Primary
leiomyosarcoma of bone: a report on three patients,” Clinical
Imaging, vol. 32, no. 4, pp. 321–325, 2008.
[5] O. Berlin, L. Angervall, and L. G. Kindblom, “Primary
leiomyosarcoma of bone. A clinical, radiographic, pathologic-
anatomic, and prognostic study of 16 cases,” Skeletal Radiol-
ogy, vol. 16, no. 5, pp. 364–376, 1987.
[6] M. C. Bouaziz, S. Chaabane, K. Mrad et al., “Primary
leiomyosarcoma of bone: report of 4 cases,” Journal of Com-
puter Assisted Tomography, vol. 29, no. 2, pp. 254–259, 2005.
[7] T. Goto, T. Ishida, N. Motoi et al., “Primary leiomyosarcoma
of the femur,” Journal of Orthopaedic Science, vol. 7, no. 2, pp.
267–273, 2002.
[8] S. Hannachi, R. Khattech, R. Dhouib et al., “[Primary bone
leiomyosarcoma. Anatomo-clinical, immunohistochemical,
and ultrastructural study],” Revue de Chirurgie Orthopedique
etReparatricede lAppareil Moteur, vol. 85, no. 8, pp. 865–870,
1999.
[9] J. L. Myers, J. Arocho, W. Bernreuter, W. Dunham, and M.
T. Mazur, “Leiomyosarcoma of bone. A clinicopathologic,
immunohistochemical,andultrastructuralstudyofﬁvecases,”
Cancer, vol. 67, no. 4, pp. 1051–1056, 1991.
[10] B. Rekhi, A. Kaur, A. Puri, S. Desai, and N. A. Jambhekar,
“Primary leiomyosarcoma of bone—a clinicopathologic study
of 8 uncommon cases with immunohistochemical analysis
and clinical outcomes,” Annals of Diagnostic Pathology, vol. 15,
no. 3, pp. 147–156, 2011.
[11] M. P. A. Young and A. J. Freemont, “Primary leiomyosarcoma
of bone,” Histopathology, vol. 19, no. 3, pp. 257–262, 1991.
[ 1 2 ]M .K h o d d a m i ,Y .C .B ´ edard, R. S. Bell, and R. A. Kandel,
“Primary leiomyosarcoma of bone: report of seven cases and
review of the literature,” Archives of Pathology and Laboratory
Medicine, vol. 120, no. 7, pp. 671–675, 1996.
[13] C.L.Young,L.E.Wold,R.A.McLeod,andF.H.Sim,“Primary
leiomyosarcoma of bone,” Orthopedics, vol. 11, no. 4, pp. 615–
618, 1988.
[14] K. Templeton, “Leiomyosarcoma of bone,” American Journal
of Orthopedics, vol. 34, no. 5, pp. 249–251, 2005.
[15] L. C. Carter, A. Aguirre, B. Boyd, and M. D. Delacure,
“Primaryleiomyosarcomaofthemandibleina7-year-oldgirl:
reportofacaseandreviewoftheliterature,”OralSurgery,Oral
Medicine,OralPathology,OralRadiology,andEndodontics,vol.
87, no. 4, pp. 477–484, 1999.
[16] M. Ikram, I. Ahmed, D. Ahmed, and Y. I. Ahmed,
“Leiomyosarcoma of the maxilla with spinal metastasis: a case
report,” Ear, Nose and Throat Journal, vol. 82, no. 6, pp. 458–
460, 2003.
[17] K. Izumi, T. Maeda, J. Cheng, and T. Saku, “Primary
leiomyosarcoma of the maxilla with regional lymph node
metastasis. Report of a case and review of the literature,” Oral
Surgery, Oral Medicine, Oral Pathology, Oral Radiology and,
vol. 80, no. 3, pp. 310–319, 1995.
[18] A. L. Soderholm, C. Lindqvist, L. Teppo, J. Wolf, and J. Sane,
“Boneresectioninpatientswithmandibularsarcoma,”Journal
of Cranio-Maxillo-Facial Surgery, vol. 16, no. 5, pp. 224–230,
1988.
[19] J. A. Ursick and F. H. Linthicum, “Leiomyosarcoma of the
temporal bone,” Otology and Neurotology, vol. 32, no. 4, pp.
e30–e31, 2011.
[20] I. J. Lewis, M. A. Nooij, J. Whelan et al., “Improvement in
histologic response but not survival in osteosarcoma patients
treatedwithintensiﬁedchemotherapy:arandomizedphaseIII
trial of the european osteosarcoma intergroup,” Journal of the
National Cancer Institute, vol. 99, no. 2, pp. 112–128, 2007.
[21] J. Whelan, R. Jinks, A. McTiernan et al., “Survival from
high grade localised extremityosteosarcoma: combined results
and prognostic factors from three European Osteosarcona
Intergroup randomised controlled trials,” Annals of Oncology.
In press.Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com